^1^1C-methionine

Phase 2Small molecule

SSt. Jude Children's Research Hospital

^1^1C-methionine is one of 35 small molecule programs targeting Ependymoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpendymomaActive, not recruiting

RhabdomyosarcomaActive, not recruiting

EpendymomaPhase 2

Active, not recruiting

RhabdomyosarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Rhabdomyosarcoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

16 2

Verzenio

Eli Lilly

Approved

—3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 4

Camptosar

Pfizer

Phase 3

8 5

Oncovin

Eli Lilly

Phase 3

6 6

Adriamycin

Pfizer

Phase 3

6 7

Cosmegen

RRECORDATI GROUP

Phase 3

17 8

Ifex

BBaxter Healthcare Corporation

Phase 3

8 9

Vepesid

AAvyxa

Phase 3

7 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Ependymoma

NCT02125786

Q2 2030

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT01871766

Q2 2031

Phase 2Active, not recruiting

Craniopharyngioma

NCT01419067

Clinical

Trials by Indication[1]

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Ependymoma1 trial

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02125786·68 enrolled

Craniopharyngioma1 trial

A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01419067·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ^1^1C-methionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ^1^1C-methionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ^1^1C-methionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

^1^1C-methionine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2030

Q2 2031

Trials by Indication[1]

Rhabdomyosarcoma1 trial

Ependymoma1 trial

Craniopharyngioma1 trial

References

Drug Info

Quick Facts

Related News